Talaris Therapeutics, Inc. (TALS)

Talaris Therapeutics, Inc. (TALS) — VMCI valuation read

Talaris Therapeutics, Inc. (TALS) carries a VMCI composite of 39/100, 11 points below the Healthcare sector median of 50. Among mid-cap names, that gap places TALS in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The TALS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads TALS trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.8x is the rate-sensitivity line to watch, the line to track on Talaris Therapeutics, Inc.'s next 10-Q.

TALS fell 3.8% over the trailing 7 days, with a +5.5% read on a 30-day basis.